GlassScriptPhysician profile
Catherine A Obin
NPI 1841286739
$2,512.53
in general payments reported to CMS, 2019-2025
17 companies · $805 in 2025
The $805 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $126 · 2022: $470 · 2023: $330 · 2024: $781 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,867 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,866.84 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $316.63 | 2022-2025 | Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $304.87 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $249.97 | 2022-2024 | Rexulti |
| Abbvie INC. | $226.77 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $157.49 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.35 | 2021-2024 | Jardiance |
| Novo Nordisk INC | $133.80 | 2021-2024 | Wegovy |
| Astellas Pharma US INC | $125.00 | 2023 | Veozah |
| Lilly USA, LLC | $124.99 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $120.23 | 2025 | Neffy |
| Mylan Specialty L.P. | $105.16 | 2023 | Yupelri |
| Janssen Scientific Affairs, LLC | $103.55 | 2022 | |
| Hologic Sales and Service, LLC | $100.50 | 2025 | Aptima |
| Sage Therapeutics, LLC | $100.04 | 2023 | |
| Sanofi-Aventis U.S. LLC | $83.82 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $71.41 | 2025 | Tarpeyo |
| Abbott Laboratories | $49.95 | 2025 | Freestyle Insulinx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Obin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.